Diethylstibesterol
Tuesday, 20 October 2026
Contributions
Jessica Toale (Bournemouth West) (Lab)Labour
6. What steps her Department is taking to support women affected by diethylstilbesterol.
The Minister for Public Health and Patient Safety (Dame Diana Johnson)Labour
I pay tribute to my hon. Friend for all her campaigning on diethylstilbesterol and to her constituent Jan Hall and her family. We recognise the serious intergenerational effects of exposure to DES, including increased cancer risks and reproductive complications, and we have asked NHS England and clinical networks to improve awareness of those issues and the people affected by them. We have commissioned an evidence review of the intergenerational effects of DES, which will inform our efforts to strengthen support in this area.
I thank the Minister for her answer and the constructive way in which the Department of Health and Social Care has engaged with me and campaigners from DES Justice UK, but I am still meeting women who are being denied breast cancer screening, colposcopies and other things that are essential for their care, despite the letter from the cancer alliance about DES exposure risk. How can we ensure that GPs and other health professionals are truly aware of the risks of DES, and that the women who need the support can get it when they need it?
I recognise that some women exposed to DES still face difficulties accessing advice, monitoring and referral. Clinicians should consider individual medical histories, symptoms and risk factors. I had a look at the letter that was sent on 12 December explaining what more should be done by clinicians. I will again ask officials to look at whether we need to reissue that letter or whether we need to take any other action to ensure that the information about DES is spread as widely as possible among clinicians.
Alison Bennett (Mid Sussex) (LD)Liberal Democrat
I am pleased that the Minister is talking about ensuring that medical professionals are more aware of DES and the risks for those who were potentially exposed to it, but what is her assessment of the feasibility of tracking and informing those who were potentially exposed? My constituent Heather did not realise that she—or her mother—had been exposed until long after her mother’s death.
As I just said, the Government are improving identification and support for people affected by DES by raising awareness among clinicians and strengthening the dissemination of existing NHS guidance. There are considerable challenges associated with recalling records from the 1940s to the 1970s, particularly because of the record-keeping practices of that era and the fact that the Medicines and Healthcare products Regulatory Agency had not yet been established at that time, but I am mindful of the point that the hon. Member makes.
Source: UK Parliament Hansard API. Debate ID: 5420661.